Design Therapeutics Inc (DSGN)
3.71
-0.11
(-2.88%)
USD |
NASDAQ |
Jun 14, 16:00
3.71
0.00 (0.00%)
After-Hours: 20:00
Design Therapeutics Net Income (Quarterly): -11.10M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -11.10M |
December 31, 2023 | -11.84M |
September 30, 2023 | -15.79M |
June 30, 2023 | -19.94M |
March 31, 2023 | -19.29M |
December 31, 2022 | -17.34M |
September 30, 2022 | -17.70M |
June 30, 2022 | -15.00M |
March 31, 2022 | -13.26M |
Date | Value |
---|---|
December 31, 2021 | -11.06M |
September 30, 2021 | -11.32M |
June 30, 2021 | -7.636M |
March 31, 2021 | -5.514M |
December 31, 2020 | -3.855M |
September 30, 2020 | -2.32M |
June 30, 2020 | -1.442M |
March 31, 2020 | -0.663M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-19.94M
Minimum
Jun 2023
-0.663M
Maximum
Mar 2020
-10.89M
Average
-11.32M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
Biogen Inc | 393.40M |
AbbVie Inc | 1.369B |
PTC Therapeutics Inc | -91.58M |
Revance Therapeutics Inc | -53.15M |
Context Therapeutics Inc | -3.668M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 14.40M |
EPS Diluted (Quarterly) | -0.20 |
Enterprise Value | -61.09M |
Earnings Yield | -28.30% |